Last reviewed · How we verify

ProAir — Competitive Intelligence Brief

ProAir (albuterol) competitive landscape: 0 comparators, recent regulatory actions, upcoming PDUFA, patent timeline. Class: SABA (Short-acting beta-2 agonist). Area: Respiratory.

marketed SABA (Short-acting beta-2 agonist) Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor Respiratory Small molecule Live · refreshed every 30 min

Target snapshot

ProAir (albuterol) — Generic (originally Allen & Hanburys/GSK). Short-acting beta-2 adrenergic agonist (SABA) that relaxes bronchial smooth muscle, providing rapid relief of bronchospasm.

Comparator set

Auto-detected by same drug class / molecular target / therapeutic area, ranked by phase + recency. Override with ?vs=slug1,slug2,….

DrugGenericSponsorPhaseClassTargetApproval / PDUFA
ProAir TARGET albuterol Generic (originally Allen & Hanburys/GSK) marketed SABA (Short-acting beta-2 agonist) Beta-1 adrenergic receptor, Beta-2 adrenergic receptor, Beta-2 adrenergic receptor 1982-05-05

Recent regulatory actions (last 90 days)

No regulatory actions in the last 90 days for this set.

Upcoming PDUFA dates (next 180 days)

No PDUFA dates in the next 180 days for this set.

Patent timeline (forward window)

No upcoming patent expiries for this set.

Sponsor landscape (SABA (Short-acting beta-2 agonist) class)

  1. Generic (originally Allen & Hanburys/GSK) · 1 drug in this class

Subscribe to ongoing alerts

Push every new event for this competitive set into your RSS reader, IFTTT/Zapier workflow, or email digest:

Cite this brief

Drug Landscape (2026). ProAir — Competitive Intelligence Brief. https://druglandscape.com/ci/albuterol. Accessed 2026-05-13.

Build your own brief

Pick any drug + add comparators: